AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Haemonetics Corporation
XNYS · usd
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001S6QB64
118.51▲ 2.35 (2.02%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
116.16
Day's Range
115.49 – 119.20
52-Week Range
48.98 – 123.77
Volume
777.3K
Avg Volume
681.0K
Share Statistics
Shares Outstanding
Employees
3,023
Exchange
XNYS
Listed
1991-05-09
Share count as of July 31, 2026

Haemonetics Corporation (HAE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Haemonetics Corporation (HAE)
What is Haemonetics Corporation's Market Cap?
Haemonetics Corporation's Market Cap is $5.4B, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Enterprise Value?
Haemonetics Corporation's Enterprise Value is $6.3B, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Trailing P/E?
Haemonetics Corporation's Trailing P/E is 56.0×, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Price / Sales?
Haemonetics Corporation's Price / Sales is 4.0×, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's EV / Revenue?
Haemonetics Corporation's EV / Revenue is 4.7×, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's EV / EBITDA?
Haemonetics Corporation's EV / EBITDA is 23.5×, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Revenue (TTM)?
Haemonetics Corporation's Revenue (TTM) is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Net Income (TTM)?
Haemonetics Corporation's Net Income (TTM) is $96.3M, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's EBITDA?
Haemonetics Corporation's EBITDA is $270.4M, based on as-reported figures from SEC (XBRL) filings.
What is Haemonetics Corporation's Diluted EPS (TTM)?
Haemonetics Corporation's Diluted EPS (TTM) is 2.12, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · HAEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 27, 2026Mar 28, 2026Dec 27, 2025Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 28, 2024Sep 28, 2024Jun 29, 2024Mar 30, 2024Dec 30, 2023Sep 30, 2023Jul 1, 2023Apr 1, 2023Dec 31, 2022Oct 1, 2022Jul 2, 2022
Net revenues
YoY growth+5.6%+4.8%-2.7%-5.3%-4.4%
Cost of goods sold
Gross profit
% of revenue59.8%57.2%59.7%59.5%59.8%
Operating expenses:
Research and development
Selling, general and administrative
Amortization of acquired assets
Total operating expenses
% of revenue42.8%63.9%39.8%41.6%43.1%
Operating income
% of revenue16.9%-6.6%19.9%17.9%16.8%
Interest and other expense, net
Income before provision for income taxes
Provision for income taxes
Net income
% of revenue9.7%-5.8%13.2%11.8%10.6%
Basic (in dollars per share)
Diluted (in dollars per share)